[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 34.85, "open": 34.155, "dayLow": 33.15, "dayHigh": 35.14, "regularMarketPreviousClose": 34.85, "regularMarketOpen": 34.155, "regularMarketDayLow": 33.15, "regularMarketDayHigh": 35.14, "payoutRatio": 0.0, "beta": 2.207, "trailingPE": 138.1996, "forwardPE": 35.618454, "volume": 2369614, "regularMarketVolume": 2369614, "averageVolume": 3045644, "averageVolume10days": 3950170, "averageDailyVolume10Day": 3950170, "bid": 29.91, "ask": 39.41, "bidSize": 1, "askSize": 1, "marketCap": 5485694976, "fiftyTwoWeekLow": 15.16, "fiftyTwoWeekHigh": 46.48, "priceToSalesTrailing12Months": 14.197448, "fiftyDayAverage": 38.5172, "twoHundredDayAverage": 29.908224, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5004540416, "profitMargins": 0.10132, "floatShares": 135549062, "sharesOutstanding": 158776000, "sharesShort": 23543502, "sharesShortPriorMonth": 26233481, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1499, "heldPercentInsiders": 0.09696, "heldPercentInstitutions": 0.61777, "shortRatio": 8.19, "shortPercentOfFloat": 0.16540001, "impliedSharesOutstanding": 158776000, "bookValue": 1.544, "priceToBook": 22.376879, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": 39150000, "trailingEps": 0.25, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 12.952, "enterpriseToEbitda": 83.58, "52WeekChange": 1.0596926, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 34.5499, "targetHighPrice": 55.0, "targetLowPrice": 11.0, "targetMeanPrice": 43.5, "targetMedianPrice": 48.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 311000000, "totalCashPerShare": 2.141, "ebitda": 59877000, "totalDebt": 254380000, "totalRevenue": 386385984, "debtToEquity": 114.398, "revenuePerShare": 2.657, "grossProfits": 337800000, "revenueGrowth": 0.904, "grossMargins": 0.87426, "ebitdaMargins": 0.15496999, "operatingMargins": 0.071339995, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "shortName": "TG Therapeutics, Inc.", "regularMarketChangePercent": -0.86111456, "regularMarketPrice": 34.5499, "corporateActions": [], "regularMarketTime": 1746725434, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "averageDailyVolume3Month": 3045644, "fiftyTwoWeekLowChange": 19.3899, "fiftyTwoWeekLowChangePercent": 1.2790172, "fiftyTwoWeekRange": "15.16 - 46.48", "fiftyTwoWeekHighChange": -11.9300995, "fiftyTwoWeekHighChangePercent": -0.25667167, "fiftyTwoWeekChangePercent": 105.96926, "earningsTimestamp": 1746442800, "earningsTimestampStart": 1754310600, "earningsTimestampEnd": 1754656200, "earningsCallTimestampStart": 1746448200, "earningsCallTimestampEnd": 1746448200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.25, "epsForward": 0.97, "epsCurrentYear": 0.95197, "priceEpsCurrentYear": 36.293056, "fiftyDayAverageChange": -3.9673004, "fiftyDayAverageChangePercent": -0.103000745, "twoHundredDayAverageChange": 4.641676, "twoHundredDayAverageChangePercent": 0.15519731, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "firstTradeDateMilliseconds": 1272893400000, "regularMarketChange": -0.30009842, "regularMarketDayRange": "33.15 - 35.14", "fullExchangeName": "NasdaqCM", "longName": "TG Therapeutics, Inc.", "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]